L
Luana Calabrò
Researcher at University of Siena
Publications - 112
Citations - 5013
Luana Calabrò is an academic researcher from University of Siena. The author has contributed to research in topics: Tremelimumab & Ipilimumab. The author has an hindex of 28, co-authored 101 publications receiving 4083 citations. Previous affiliations of Luana Calabrò include University of Messina & Istituto Superiore di Sanità.
Papers
More filters
Journal ArticleDOI
High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
Mariantonia Logozzi,Angelo De Milito,Luana Lugini,Martina Borghi,Luana Calabrò,Massimo Spada,Maurizio Perdicchio,Maria Marino,Cristina Federici,Elisabetta Iessi,Daria Brambilla,Giulietta Venturi,Francesco Lozupone,Mario Santinami,Veronica Huber,Michele Maio,Licia Rivoltini,Stefano Fais +17 more
TL;DR: The results suggest that the Exotest for detection of plasma exosomes carrying tumor-associated antigens may represent a novel tool for clinical management of cancer patients.
Journal ArticleDOI
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio,Arnaud Scherpereel,Luana Calabrò,Joachim G.J.V. Aerts,Susana Cedres Perez,Alessandra Bearz,Kristiaan Nackaerts,Dean A. Fennell,Dariusz M. Kowalski,Anne S. Tsao,Paul D. Taylor,Federica Grosso,Scott J. Antonia,Anna K. Nowak,Anna K. Nowak,Maria Taboada,Martina Puglisi,Paul K. Stockman,Hedy L. Kindler +18 more
TL;DR: The DETERMINE study investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma and overall survival was overall survival in the intention-to-treat population.
Journal ArticleDOI
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi,Johan Vansteenkiste,David R. Spigel,Hidenobu Ishii,Marina Chiara Garassino,Filippo de Marinis,Mustafa Ozguroglu,Aleksandra Szczesna,Andreas Polychronis,Ruchan Uslu,Maciej Krzakowski,Jong Seok Lee,Luana Calabrò,Osvaldo Arén Frontera,Barbara Ellers-Lenz,Marcis Bajars,M. Ruisi,Keunchil Park +17 more
TL;DR: This trial investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy and found median overall survival did not differ significantly between the aVELumab and docetaxel groups.
Journal ArticleDOI
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabrò,Aldo Morra,Ester Fonsatti,Ornella Cutaia,Giovanni Amato,Diana Giannarelli,Anna Maria Di Giacomo,Riccardo Danielli,Maresa Altomonte,Luciano Mutti,Michele Maio +10 more
TL;DR: Although the effect size was small in the phase 2 trial, tremelimumab seemed to have encouraging clinical activity and an acceptable safety and tolerability profile in previously treated patients with advanced malignant mesothelioma.
Journal ArticleDOI
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo,Riccardo Danielli,Massimo Guidoboni,Luana Calabrò,Dora Carlucci,Clelia Miracco,Luca Volterrani,Maria Antonietta Mazzei,Maurizio Biagioli,Maresa Altomonte,Michele Maio +10 more
TL;DR: Three patients with advanced melanoma, who experienced progressive disease after a variety of previous therapies, including prior immunotherapies, and who achieved good outcomes with ipilimumab are reported on, highlighting the potential for anti-CTLA-4-based therapy in previously treated patients withadvanced melanoma.